
|Articles|September 7, 2007
AMD eye drops trial kicks off
TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).
Advertisement
TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).
TG100801 is administered non-invasively as an eye drop and has been developed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, oedema and angiogenesis.
A second topically applied compound for eye disease, TG100948, is also in early development.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
Port Delivery System Therapies in Retinal Vascular Diseases
5






















